New drug CR-001 enters human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This study tests a new drug, CR-001, in adults with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. About 290 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC